Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review

Failure in cancer drug development exacts heavy burdens on patients and research systems. To investigate inefficiencies and burdens in targeted drug development in cancer, we conducted a systematic review of all prelicensure trials for the anticancer drug, sorafenib (Bayer/Onyx Pharmaceuticals). We...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattina, James, Carlisle, Benjamin, Hachem, Yasmina, Fergusson, Dean, Kimmelman, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Meta-Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291369/
https://www.ncbi.nlm.nih.gov/pubmed/28158308
http://dx.doi.org/10.1371/journal.pbio.2000487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291369/
https://www.ncbi.nlm.nih.gov/pubmed/28158308
http://dx.doi.org/10.1371/journal.pbio.2000487

Ejemplares similares